AI-powered DILI prediction: modernizing drug development, speeding decisions and reducing risk.
Learn more about Libra
Integrated within ToxStudio®, Libra modernizes preclinical safety assessments by addressing drug-induced liver injury (DILI).
Discover Libra, the innovative tool that transforms DILI prediction in early drug discovery. By optimizing resources, reducing animal testing, and enhancing patient safety, Libra is your key to smarter, safer drug development.
Achieve up to 85% accuracy in DILI prediction, reducing failures and ensuring more reliable outcomes throughout drug discovery and development.
Libra saves time and resources by identifying high-risk candidates early, enabling faster decision-making with advanced DILI prediction software.
Minimize reliance on in vivo studies while maintaining robust safety data with Libra, supporting ethical and sustainable drug development practices.
Libra is a catalyst for transformation in drug development, using machine learning to enhance DILI prediction, streamline safety assessments, and fit seamlessly into existing workflows.
Vice President, Quantitative Systems Toxicology and Safety
Will 带领 QSTS 团队应用计算方法来评估药物和其他化学品的安全性。他是一位经验丰富的安全药理学家，曾在 Syntex、Quintiles 和 AstraZeneca 任职。他是安全性药理学协会的前任主席。
建立联系
Senior Research Scientist
Barira Islam, PhD is a Senior Research Scientist in QSTS division of Certara Predictive Technologies, UK. She is a Chemist by training and joined Certara in 2021. She leads the libra project and has also contributed to other projects, including RISK-HUNT3R (EU project) and Secondary Intelligence.
建立联系Ready to advance your drug development process with industry-leading DILI prediction software and AI-driven insights? Contact us today to discover how Libra, a cutting-edge DILI prediction tool, can seamlessly integrate into your preclinical workflows and accelerate your path to success.
Libra is an AI-driven tool developed by Certara to predict drug-induced liver injury (DILI) with high precision, enhancing decision-making and reducing risks in drug development.
Libra uses quantitative structure-activity relationship (QSAR) modeling and Bayesian machine learning to integrate physicochemical and in vitro assay data, providing actionable insights into potential DILI risks.
Libra offers good predictive accuracy (up to 85%), accelerates development timelines by identifying high-risk candidates early, and promotes ethical practices by reducing reliance on animal testing.
Libra provides clear, customizable results designed to fit seamlessly into your existing workflows, enhancing collaboration across teams and ensuring minimal disruption.
In brief, Libra takes whatever relevant data you have available at different stages throughout the discovery phase, starting with molecular structure (for the QSAR model) then physicochemical characteristics, and on to in vitro DILI-related assay readouts. It thereby transitions from hazard detection to integrated risk assessment.
Libra offers an integrated approach within Certara’s ToxStudio® suite, alongside platforms like Cardiac Safety Simulator™ and Secondary Intelligence™, solidifying Certara’s leadership in modernizing preclinical safety assessments.
To learn how Libra can integrate seamlessly into your preclinical workflows, you can contact Certara through our website to get more information and support. A prototype demo version of Libra is available for you to evaluate in-house (free-of-charge; no obligation to purchase). We would welcome your feedback on the tool.
© 2025 Certara. 保留所有权力。 | 隐私政策
